KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) EBT Margin (2016 - 2025)

NovoCure (NVCR) has disclosed EBT Margin for 12 consecutive years, with 23.49% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 1074.0% to 23.49% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 20.79% through Dec 2025, up 88.0% year-over-year, with the annual reading at 20.79% for FY2025, 88.0% up from the prior year.
  • EBT Margin hit 23.49% in Q4 2025 for NovoCure, down from 17.96% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 1.83% in Q1 2022 to a low of 42.76% in Q2 2023.
  • Historically, EBT Margin has averaged 21.05% across 5 years, with a median of 19.37% in 2021.
  • Biggest five-year swings in EBT Margin: crashed -3998bps in 2023 and later soared 2765bps in 2024.
  • Year by year, EBT Margin stood at 19.2% in 2021, then plummeted by -32bps to 25.35% in 2022, then decreased by -14bps to 28.8% in 2023, then dropped by -19bps to 34.23% in 2024, then soared by 31bps to 23.49% in 2025.
  • Business Quant data shows EBT Margin for NVCR at 23.49% in Q4 2025, 17.96% in Q3 2025, and 22.03% in Q2 2025.